October 8, 2018 (Los Angeles) – International law firm Proskauer represented Clarus Ventures in its sale to The Blackstone Group (NYSE: BX). The transaction is expected to close in the fourth quarter of 2018.  

The acquisition launches Blackstone Life Sciences, and is part of Blackstone’s efforts to scale up its investments in health care.

Clarus is a leading global investment firm dedicated to life sciences. Clarus manages more than $2.6 billion, and has invested in more than 50 private and public companies in the biotechnology, medical device and diagnostic spaces.

The Proskauer team was led by partners Robin Painter, Jonathan Benloulou and Christopher Wu, and included associates Jessica Sabbah-Mani, Liam Gallagher and Orlie Golan (Mergers & Acquisitions); associates Stephen Meli, Brad Schecter and Frank Pustorino (Private Funds); partners Anne Kim and Jeremy Naylor and associates Stephen Severo and Kimberly Condoulis (Tax); partners Michael Album and Joshua Miller and associate Oleg Zakatov (Employee Benefits & Executive Compensation); senior counsel John Ingrassia (Antitrust); and associate Carlu Franceschini (Intellectual Property).

Over the past three years, Proskauer’s Private Equity and Mergers & Acquisitions Group has advised on hundreds of M&A transactions with an aggregate value of over $200 billion. We provide strategic, disciplined and commercial advice geared towards achieving our clients’ goals in an efficient and practical manner. Our group has represented clients in a wide variety of industries, including consumer/retail, energy and power, financial services, health care, industrials, infrastructure, life sciences, media and entertainment, natural resources, real estate, sports, technology and telecommunications.